Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity

Conclusion: Serum VEGF levels in patients with Type 1 ROP were suppressed for 2 months after treatment with IVB, and VEGF levels were less affected after IVR treatment. Further studies are warranted to investigate the long-term effects of VEGF changes in ROP patients.
Source: RETINA - Category: Opthalmology Tags: Original Study Source Type: research